Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed
Eureka, California has become the latest city to decriminalize psychedelic medicines. The city council adopted a resolution this week that moves psychedelics (Entheogenic Plants and Fungi) to the lowest priority level for law enforcement.
“… planting, cultivating, purchasing, transporting, distributing, engaging in practices with, or possessing Entheogenic Plants and Fungi or their extracted compounds that are on the Federal Schedule I list … will not be a public safety priority for the City of Eureka.”
Harvard is creating a new Study of Psychedelics in Society and Culture. The study will be an interdisciplinary endeavor across the Faculty of Arts and Sciences, Harvard Law School, and Harvard Divinity School. The goal is to “transform the psychedelics research landscape by producing cutting-edge scholarship and convening faculty, students, and experts to engage in discussion around their far-reaching implications.”
Former Tesla director Antonio Gracias made this move possible by donating $16 million to Harvard to study psychedelics in society and culture.
Johnson & Johnson has released its 3rd quarter results and once again Spravato sales have shown impressive growth. Spravato sales have logged the biggest % growth in J&J’s portfolio — a whopping 82% increase in sales compared to the 3rd quarter last year.
$182 million in revenue in the third quarter. Not bad. Especially considering that just a tiny fraction of doctors are educated on psychedelics and prescribing Spravato.
The psychedelic medicine community has lost one of its great figures as Dr. Roland Griffiths has passed away.
Roland Griffiths, Ph.D., was a Professor of Psychiatry and Neurosciences at the Johns Hopkins University School of Medicine, and founding Director of the Johns Hopkins Center on Psychedelic and Consciousness Research. He was a world-renowned psychopharmacologist whose research helped to revive interest in the therapeutic potential of psychedelic drugs.
Dr. Griffiths had been battling terminal cancer for the last few years, yet still managed to keep up his work and advocacy, becoming an even more public and inspiring figure as he moved through the final stages of his journey.
“The closing of this transaction marks a significant milestone in Cybin’s growth trajectory, firmly establishing us as a leader in the psychedelics sector,” said Doug Drysdale, Chief Executive Officer of Cybin.
“We welcome the Small Pharma scientists and leaders who are joining the Cybin team, as we look to leverage the many synergies and drive value for shareholders.”
Want to catch up on more industry news? Check out a previous edition of the News You Might Have Missed
psychedelics psychedelic cybin revive small pharma decriminalization research